托珠單抗聯(lián)合甲氨蝶呤治療難治性類風(fēng)濕關(guān)節(jié)炎的療效觀察
發(fā)布時(shí)間：2018-11-21 20:35
【摘要】：目的·探討托珠單抗聯(lián)合甲氨蝶呤治療難治性中重度活動(dòng)的類風(fēng)濕關(guān)節(jié)炎(RA)的有效性及安全性。方法·10例難治性活動(dòng)性RA患者接受足量托珠單抗注射液聯(lián)合甲氨蝶呤口服治療,觀察治療前(基線)及治療第12、24周時(shí)壓痛關(guān)節(jié)數(shù)、腫脹關(guān)節(jié)數(shù)、紅細(xì)胞沉降率(ESR)、C反應(yīng)蛋白(CRP)及疾病活動(dòng)指數(shù)28(DAS28)、簡(jiǎn)化疾病活動(dòng)指數(shù)(SDAI)和臨床疾病活動(dòng)指數(shù)(CDAI)等指標(biāo)的變化,記錄不良反應(yīng)發(fā)生情況。結(jié)果·與治療前比較,治療后第12周和第24周RA患者的關(guān)節(jié)癥狀、體征、ESR及DAS28、CDAI、SDAI等指標(biāo)均有不同程度改善,差異均有統(tǒng)計(jì)學(xué)意義(P0.05)。無(wú)白細(xì)胞減少、心功能不全及嚴(yán)重感染等不良反應(yīng)發(fā)生。結(jié)論·托珠單抗能快速并顯著地改善難治性活動(dòng)性RA患者的臨床癥狀、體征、活動(dòng)性指標(biāo)及關(guān)節(jié)炎評(píng)分。
[Abstract]:Objective to investigate the efficacy and safety of Todzumab combined with methotrexate in the treatment of refractory moderate and severe active rheumatoid arthritis (RA). Methods Ten patients with refractory active RA were treated with adequate tubeumab injection combined with methotrexate orally. The number of tenderness joints, the number of swollen joints and erythrocyte sedimentation rate (ESR),) were observed before treatment (baseline) and 24 weeks after treatment. C-reactive protein (CRP), disease activity index (DAS28), simplified disease activity index (SDAI) and clinical disease activity index (CDAI) were recorded. Results compared with before treatment, the joint symptoms, signs, ESR and DAS28,CDAI,SDAI of RA patients were improved in different degree after 12 weeks and 24 weeks of treatment, and the differences were statistically significant (P0.05). No leukopenia, cardiac insufficiency and severe infection occurred. Conclusion Torzumab can improve the clinical symptoms, signs, activity indexes and arthritis score of refractory active RA patients quickly and significantly.
【作者單位】： 上海交通大學(xué)醫(yī)學(xué)院附屬仁濟(jì)醫(yī)院南院風(fēng)濕科;
【分類號(hào)】：R593.22
[Abstract]:Objective to investigate the efficacy and safety of Todzumab combined with methotrexate in the treatment of refractory moderate and severe active rheumatoid arthritis (RA). Methods Ten patients with refractory active RA were treated with adequate tubeumab injection combined with methotrexate orally. The number of tenderness joints, the number of swollen joints and erythrocyte sedimentation rate (ESR),) were observed before treatment (baseline) and 24 weeks after treatment. C-reactive protein (CRP), disease activity index (DAS28), simplified disease activity index (SDAI) and clinical disease activity index (CDAI) were recorded. Results compared with before treatment, the joint symptoms, signs, ESR and DAS28,CDAI,SDAI of RA patients were improved in different degree after 12 weeks and 24 weeks of treatment, and the differences were statistically significant (P0.05). No leukopenia, cardiac insufficiency and severe infection occurred. Conclusion Torzumab can improve the clinical symptoms, signs, activity indexes and arthritis score of refractory active RA patients quickly and significantly.
【作者單位】： 上海交通大學(xué)醫(yī)學(xué)院附屬仁濟(jì)醫(yī)院南院風(fēng)濕科;
【分類號(hào)】：R593.22
【相似文獻(xiàn)】
相關(guān)期刊論文 前10條
1 曹雙全;;對(duì)甲氨蝶呤治療炎性關(guān)節(jié)炎的評(píng)價(jià)[J];國(guó)外醫(yī)藥.合成藥.生化藥.制劑分冊(cè);1987年05期
2 張燕;;甲氨蝶呤過量致便血1例[J];中國(guó)中西醫(yī)結(jié)合消化雜志;2006年03期
3 李進(jìn)峰;閆秀娟;張媛;;甲氨蝶呤引起急性肝損傷1例[J];北方藥學(xué);2013年11期
4 何曉瑾;金實(shí);;痛痹方聯(lián)合甲氨蝶呤治療活動(dòng)期類風(fēng)濕性關(guān)節(jié)炎30例臨床研究[J];江蘇中醫(yī)藥;2007年02期
5 楊俊華,鄭金聰;甲氨蝶呤臨床新用途[J];新醫(yī)學(xué);1991年11期
6 路杰;許勇芝;唐德q，
本文編號(hào)：2348198
本文鏈接：http://sikaile.net/yixuelunwen/nfm/2348198.html
最近更新
教材專著
